Watson receives FDA product approval for India facility

During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is expected to be producing over 1 billion tablets and capsules annually for the US market.

“This approval represents a key milestone for Watson, demonstrating our rapid progress toward building an offshore infrastructure,” said Allen Chao, Watson’s executive chairman.

“In the coming months we anticipate making additional FDA submissions to transfer certain products to this facility to achieve efficiencies in scale and cost. This will enhance our ability to provide quality, low cost generic pharmaceutical products to the US marketplace.”